Aethlon Medical (AEMD) Stock Rockets 471% Following North Immunology Merger Announcement
Key HighlightsShares of Aethlon Medical skyrocketed more than 471% during premarket hours on September 17, 2026, following the announcement of a merger with North ImmunologyThe transaction is structured as an all-stock merger that will result in a newly formed Nasdaq-listed entity named North Immunology, Inc., which will trade under ticker symbol NRTXPost-merger ownership will see North Immunology shareholders and PIPE participants controlling approximately 95% of the combined enterprise, while Aethlon stockholders will retain about 4.75%The transaction includes a $180 million concurrent private placement supported by prominent healthcare investors such as Bain Capital Life Sciences and Janus Henderson, providing runway through late 2028The companys flagship therapeutic candidate, NOR-101, a bispecific antibody targeting atopic dermatitis, is scheduled to begin Phase 1a clinical trials in early 2027 Shares of Aethlon Medical (AEMD) surged dramatically by over 471% during Thursdays premarket session following the disclosure of a definitive merger agreement with North Immunology, a private biotechnology firm. Aethlon Medical, Inc., AEMD The transaction, publicly disclosed on September 17, 2026, structures the combination through two wholly owned merger subsidiaries: Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC. Following completion of the merger, the combined organization will operate under the name North Immunology, Inc. and will maintain its









